- Home
- ODP vs AUPH Comparison
ODP vs AUPH Comparison
Compare ODP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODP
- AUPH
- Stock Information
- Founded
- ODP 1986
- AUPH 1993
- Country
- ODP United States
- AUPH Canada
- Employees
- ODP N/A
- AUPH N/A
- Industry
- ODP Other Specialty Stores
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ODP Consumer Discretionary
- AUPH Health Care
- Exchange
- ODP Nasdaq
- AUPH Nasdaq
- Market Cap
- ODP 523.7M
- AUPH 1.1B
- IPO Year
- ODP N/A
- AUPH 1999
- Fundamental
- Price
- ODP $19.20
- AUPH $7.58
- Analyst Decision
- ODP Hold
- AUPH Strong Buy
- Analyst Count
- ODP 1
- AUPH 2
- Target Price
- ODP $28.00
- AUPH $11.50
- AVG Volume (30 Days)
- ODP 471.2K
- AUPH 1.6M
- Earning Date
- ODP 08-06-2025
- AUPH 07-31-2025
- Dividend Yield
- ODP N/A
- AUPH N/A
- EPS Growth
- ODP N/A
- AUPH N/A
- EPS
- ODP N/A
- AUPH 0.27
- Revenue
- ODP $6,820,000,000.00
- AUPH $247,295,000.00
- Revenue This Year
- ODP N/A
- AUPH $12.15
- Revenue Next Year
- ODP N/A
- AUPH $18.31
- P/E Ratio
- ODP $13.78
- AUPH $28.53
- Revenue Growth
- ODP N/A
- AUPH 29.20
- 52 Week Low
- ODP $11.85
- AUPH $5.20
- 52 Week High
- ODP $43.31
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- ODP 68.66
- AUPH 40.36
- Support Level
- ODP $17.49
- AUPH $7.29
- Resistance Level
- ODP $20.04
- AUPH $8.86
- Average True Range (ATR)
- ODP 0.79
- AUPH 0.34
- MACD
- ODP 0.21
- AUPH -0.06
- Stochastic Oscillator
- ODP 90.10
- AUPH 19.37
About ODP The ODP Corporation
The ODP Corp operates an integrated B2B distribution platform with divisions focusing on various sectors: ODP Business Solutions serves small to enterprise-level companies with office supplies, technology, furniture, and services. Office Depot Division caters to retail consumers and small businesses through retail locations and eCommerce platforms, offering office supplies, technology, and business services. Veyer Division specializes in supply chain, distribution, and procurement services for both internal and third-party customers, with a focus on global operations. Varis Division offers a tech-enabled B2B indirect procurement marketplace, providing a seamless buying experience and advanced spend management tools. Revenue primarily stems from the Veyer division.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.